Omdia: Global Online Video and TV Revenues to Exceed $1 Trillion by 2030, Driven by Social Video Advertising

Omdia: Global Online Video and TV Revenues to Exceed $1 Trillion by 2030, Driven by Social Video Advertising

LONDON–(BUSINESS WIRE)–
Global traditional TV and online video revenues are projected to exceed $1 trillion by 2030, according to new data presented by Maria Rua Aguete, Head of Media & Entertainment at Omdia, at the FED Show in Madrid. Highlighting a major structural shift in the media and entertainment industry, total revenues are forecast to grow from $775 billion in 2025 to $1.03 trillion in 2030, with growth primarily driven by digital formats, especially advertising.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401036332/en/

Global traditional TV & online video revenue by type, 2025 & 2030

Global traditional TV & online video revenue by type, 2025 & 2030

Online video advertising will be the main growth engine, rising from $309 billion in 2025 to $540 billion in 2030, increasing its share of total revenues from 40% to 53%. Within the online advertising segment, social video platforms such as Meta, TikTok and YouTube will play a decisive role, generating approximately $400 billion in total streaming advertising revenues by 2030. This trend reflects a fundamental shift towards mobile-first, short-form, and highly personalized video experiences, where discovery algorithms and creator ecosystems are driving both engagement and monetization at scale.

Online video subscription and transaction revenues are projected to increase from $174 billion in 2025 to $216 billion in 2030. While this segment will continue to grow, it is entering a more mature phase, with slower growth compared to advertising-led models.

Traditional segments will continue to lose share. Linear TV advertising is expected to decline from $123 billion in 2025 to $113 billion by 2030, with its share falling from 16% to 11%. Pay TV revenues (subscriptions and transactions) will also decrease, from $169 billion to $159 billion, reflecting ongoing cord-cutting and the continued migration of audiences toward digital platforms.

“The industry is undergoing a profound transformation,” said Maria Rua Aguete. “Social video advertising is becoming the dominant force, reshaping how content is consumed and monetized. Meanwhile, traditional models such as linear TV and pay TV are in structural decline.”

As the industry approaches the $1 trillion milestone, Omdia’s analysis shows that the balance of power is shifting toward digital platforms, with advertising – led by social video – at the center of future growth.

ABOUT OMDIA

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

Fasiha Khan: [email protected]

Eric Thoo: [email protected]

KEYWORDS: Europe United Kingdom Asia Pacific

INDUSTRY KEYWORDS: TV and Radio Technology Online Marketing Advertising Entertainment Communications Social Media Other Technology Digital Marketing Content Marketing

MEDIA:

Photo
Photo
Global traditional TV & online video revenue by type, 2025 & 2030
Logo
Logo

Li Auto Inc. March 2026 Delivery Update

BEIJING, China, April 01, 2026 (GLOBE NEWSWIRE) — Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 41,053 vehicles in March 2026. As of March 31, 2026, Li Auto’s cumulative deliveries reached 1,635,357.

With the production bottleneck resolved, Li i6 monthly deliveries surpassed 24,000 units in March. The all-new Li L9 is expected to launch in the second quarter of 2026. In March, at the NVIDIA GTC 2026, the Company unveiled its next-generation autonomous driving foundation model, MindVLA, alongside its 3D ViT Encoder. They form an architecture that can directly perceive the 3D physical world with unified geometric and semantic understanding, advancing towards human-level spatial cognition.

As of March 31, 2026, the Company had 517 retail stores in 160 cities, 552 servicing centers and Li Auto-authorized servicing shops operating in 223 cities. The Company also had 4,057 super charging stations in operation equipped with 22,439 charging stalls in China.

About Li Auto Inc.

Li Auto Inc. is a leader in China’s new energy vehicle market. The Company designs, develops, manufactures, and sells premium smart electric vehicles. Its mission is: Be Proactive, Change the World (主动积极,改变世界). Through innovations in product, technology, and business model, the Company provides families with safe, convenient, and comfortable products and services. Li Auto is a pioneer in successfully commercializing extended-range electric vehicles in China. While firmly advancing along this technological route, it builds platforms for battery electric vehicles in parallel. The Company leverages technology to create value for users. It concentrates its in-house development efforts on proprietary range extension systems, innovative electric vehicle technologies, and smart vehicle solutions. The Company started volume production in November 2019. Its current model lineup includes a high-tech flagship family MPV, four Li L series extended-range electric SUVs, and two Li i series battery electric SUVs. The Company will continue to expand its product lineup to target a broader user base.

For more information, please visit: https://ir.lixiang.com.

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “targets,” “likely to,” “challenges,” and similar statements. Li Auto may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”) and The Stock Exchange of Hong Kong Limited (the “HKEX”), in its annual report to shareholders, in press releases and other written materials, and in oral statements made by its officers, directors, or employees to third parties. Statements that are not historical facts, including statements about Li Auto’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Li Auto’s strategies, future business development, and financial condition and results of operations; Li Auto’s limited operating history; risks associated with extended-range electric vehicles and high-power charging battery electric vehicles; Li Auto’s ability to develop, manufacture, and deliver vehicles of high quality and appeal to customers; Li Auto’s ability to generate positive cash flow and profits; product defects or any other failure of vehicles to perform as expected; Li Auto’s ability to compete successfully; Li Auto’s ability to build its brand and withstand negative publicity; cancellation of orders for Li Auto’s vehicles; Li Auto’s ability to develop new vehicles; and changes in consumer demand and government incentives, subsidies, or other favorable government policies. Further information regarding these and other risks is included in Li Auto’s filings with the SEC and the HKEX. All information provided in this press release is as of the date of this press release, and Li Auto does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

Li Auto Inc.
Investor Relations
Email: [email protected]

Christensen Advisory
Roger Hu
Tel: +86-10-5900-1548
Email: [email protected]



Amentum-Led Joint Venture Secures $406 Million Contract as Owner’s Engineer for UK’s First Small Modular Reactors

Amentum-Led Joint Venture Secures $406 Million Contract as Owner’s Engineer for UK’s First Small Modular Reactors

CHANTILLY, Va.–(BUSINESS WIRE)–
Great British Energy – Nuclear (GBE-N) has awarded a $406 million (£300 million) contract to a joint venture between Amentum (NYSE: AMTM) and Cavendish Nuclear to serve as the owner’s engineer for the UK’s groundbreaking small modular reactor (SMR) program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401059776/en/

Contract signing - left to right: Mick Gornall, Managing Director, Cavendish Nuclear; Loren Jones, Senior Vice President, Amentum; Simon Roddy, Chief Executive Officer, Great British Energy-Nuclear; Kenny Douglas, DevCo Director, Great British Energy-Nuclear

Contract signing – left to right: Mick Gornall, Managing Director, Cavendish Nuclear; Loren Jones, Senior Vice President, Amentum; Simon Roddy, Chief Executive Officer, Great British Energy-Nuclear; Kenny Douglas, DevCo Director, Great British Energy-Nuclear

This long-term agreement, with a maximum duration of 14 years, will support the deployment of Rolls-Royce SMR’s innovative reactor technology at the Wylfa site in North Wales. The contract represents a significant milestone in advancing the UK’s clean energy ambitions and the rollout of its first SMRs.

The Amentum-led joint venture, known as Litmus Nuclear, will play a pivotal role in the SMR program by delivering independent assurance and expert technical guidance across critical areas, including design, safety, engineering, construction, and commissioning. This support is designed to help GBE-N achieve its goal of securing a final investment decision for the deployment of SMRs at the Wylfa site.

“This award recognizes Amentum’s expertise to accelerate the global expansion and revitalization of nuclear energy. It also underscores our central role in advancing the UK’s nuclear ambitions, complementing our ongoing work at Hinkley Point C and Sizewell C,” said Loren Jones, senior vice president and head of Amentum’s Energy & Environment-International business. “Amentum will draw upon our expertise in nuclear science and engineering to provide independent technical and delivery assurance, helping GBE-N advance the SMR program and bolster the UK’s energy security and industrial base.”

The joint venture will also ensure the SMR program meets regulatory requirements and is poised to deliver reliable, low-carbon power for decades to come.

In November 2025, the UK’s Department for Energy Security and Net Zero announced Wylfa, on the island of Anglesey/Ynys Môn, as the site for the country’s first SMR’s. These 470MWe reactors are smaller and designed to be built more quickly than some traditional nuclear power stations.

About Amentum

Amentum is a global leader in advanced engineering and innovative technology solutions, trusted by the United States and its allies to address their most significant and complex challenges in science, security and sustainability.

About Amentum in the United Kingdom

With more than 6,000 people in the UK, Amentum is the delivery partner for project and construction management services at Hinkley Point C; sole program and project management delivery partner at Sizewell C; and also supports the UK’s existing nuclear power stations under a Lifetime Enterprise Agreement with EDF. It is a major supplier of engineering design, safety case and project management at Sellafield and other UK nuclear decommissioning sites and operates the country’s largest private sector complex of nuclear laboratories and engineering test facilities in Warrington.

Visit us at www.amentum.com to learn how we advance the future together.

Follow @Amentum_corp on X

Follow Amentum on LinkedIn

Forward-Looking Statements

This press release contains or incorporates by reference statements by Amentum Holdings, Inc. (the “Company”) that relate to future events and expectations and, as such, constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements may be characterized by terminology such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “forecast,” “outlook,” “target,” “endeavor,” “seek,” “predict,” “intend,” “strategy,” “plan,” “may,” “could,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” or the negative thereof or variations thereon or similar terminology generally intended to identify forward-looking statements. All statements, other than historical facts, including, but not limited to, statements regarding the anticipated work and revenue under the awarded contract, and the Company’s objectives, expectations and intentions, applicable legal, economic and regulatory conditions, and any assumptions underlying any of the foregoing, are forward-looking statements.

A number of important factors could cause actual results to differ materially from those contained in or implied by these forward-looking statements, including those factors discussed in our filings with the Securities and Exchange Commission (SEC), including, among others: the occurrence of an accident or safety incident; the ability of the Company to control costs, meet performance requirements or contractual schedules; and other factors set forth under Item 1A, Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 27, 2024, which can be found at the SEC’s website at www.sec.gov or the Investor Relations portion of our website at www.amentum.com. Any forward-looking statement speaks only as of the date on which it is made, and the Company assumes no obligation to update or revise such statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Media Contact:

Stephen Brauner

+44.7875.877120

[email protected]

Investor Contact:

Nathan Rutledge

[email protected]

KEYWORDS: Virginia North America United States Ireland United Kingdom Europe

INDUSTRY KEYWORDS: Other Defense Contracts Other Energy Professional Services Sustainability Nuclear Energy Defense Environment Homeland Security Consulting Public Policy/Government

MEDIA:

Photo
Photo
Contract signing – left to right: Mick Gornall, Managing Director, Cavendish Nuclear; Loren Jones, Senior Vice President, Amentum; Simon Roddy, Chief Executive Officer, Great British Energy-Nuclear; Kenny Douglas, DevCo Director, Great British Energy-Nuclear
Logo
Logo

IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma

IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma

Helping clinicians investigate sooner and plan next steps with confidence

WESTBROOK, Maine–(BUSINESS WIRE)–IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the availability of the IDEXX Cancer Dx™ Panel in the United Kingdom, beginning with early detection of lymphoma in at-risk* dogs. The blood test can be added to panels for sick pets and integrated into regular wellness screenings, with veterinarian pricing starting from £22.50 and results available to UK practices within 3–5 business days.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401831720/en/

IDEXX Cancer Dx Panel with lymphoma testing

IDEXX Cancer Dx Panel with lymphoma testing

Cancer remains a leading cause of canine death, with 1 in 4 dogs expected to be diagnosed with cancer in their lifetime.1 Lymphoma, one of the most common cancers, accounts for nearly a quarter of new cancer diagnoses.2 Treatment for canine lymphoma may help extend the lifespan and improve the quality of life for affected dogs, highlighting the critical need for early detection and intervention.

Research indicates that 71% of pet owners in the UK are interested in having a cancer screening test for their pet,3 signalling strong demand for proactive, wellness care.

That momentum is already visible in practice. Since the test launched in North America in 2025, nearly 6,000 veterinary practices across the United States and Canada have integrated the test into diagnostic and wellness workflows.4 The test can detect a lymphoma signal up to eight months before clinical signs appear5– helping clinicians investigate sooner and plan next steps with confidence.

“Building on more than 40 years of IDEXX’s leadership in veterinary research and technology development, IDEXX Cancer Dx is an important advancement to deliver unmatched diagnostic insights,” said Jay Mazelsky, President and Chief Executive Officer of IDEXX. “As leaders in key cancer diagnostic categories, like pathology and imaging, we continue to innovate technologies that can redefine how veterinarians approach cancer detection and monitoring in pets. We’re proud to be at the forefront of early cancer detection in dogs and delighted to expand access to reliable cancer testing in the UK.”

The IDEXX Cancer Dx Panel with lymphoma testing features:

  • Accuracy: 79% sensitivity and 99% specificity yield results that can be used with confidence for both sick dogs and in routine preventative care for at-risk dogs.6
  • Simplicity: Designed to fit seamlessly into existing veterinary workflows, clinicians can add IDEXX Cancer Dx to diagnostic and wellness panels using a single blood draw.
  • Actionable next steps: IDEXX Cancer Dx delivers qualitative results for lymphoma. In many cases, B-cell and T-cell phenotype classification will be provided with positive results.7
  • Treatment Monitoring: Early data shows that for patients with a positive Cancer Dx result at diagnosis, repeated testing can monitor remission during CHOP chemotherapy, a common treatment for canine lymphoma.8
  • Personalised guidance and comprehensive support: Every IDEXX Cancer Dx result comes with access to IDEXX Medical Consultants, including board-certified oncologists and internists, along with pet-owner education materials and resources to support client communications.
  • Deeper insights: IDEXX Preventative Care, a comprehensive portfolio of products and services supporting veterinarians in preventative care, now includes IDEXX Cancer Dx testing, unlocking additional insights for at-risk dogs.

With IDEXX Cancer Dx testing, general practitioners can now support a clinical diagnosis of lymphoma earlier than traditional diagnostics.6 Its ease of integration makes it an essential tool for practices committed to proactive cancer management.

Over the next three years, IDEXX plans to expand the Cancer Dx Panel to cover the majority of canine cancer cases, transforming cancer detection, and enabling earlier intervention. The IDEXX Cancer Dx lymphoma test is currently available to veterinary practices in the United Kingdom through the IDEXX Reference Laboratories service. For more information, visit the IDEXX Cancer Dx testing web page.

About IDEXX

IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500TM Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information about IDEXX, visit: www.idexx.com.

Note regarding forward-looking statements

This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as ‘expects’, ‘may’, ‘anticipates’, ‘intends’, ‘would’, ‘will’, ‘plans’, ‘believes’, ‘estimates’, ‘should’ and similar words and expressions. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. These statements are subject to risks, uncertainties, assumptions, and other important factors. Readers are advised not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties. IDEXX assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers are advised to review IDEXX’s filings with the United States Securities and Exchange Commission (which are available from the SEC’s EDGAR database at sec.gov and via IDEXX’s website at idexx.com).

*At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.

IDEXX reserves the right, at its sole discretion and without prior notice, to modify, revise, or otherwise amend its pricing at any time.

References

  1. What are the most common types of cancers in dogs? How many dogs typically get cancer? Veterinary Cancer Society; 2021. Accessed January 16, 2024. www.vetcancersociety.org/pet-owners/faqs.

  2. Vail DM, Pinkerton M, Young KM. Hematopoietic tumours. In: Vail DM, Thamm DH, Liptak JM, eds. Withrow and MacEwen’s Small Animal Clinical Oncology. 6th ed. Saunders; 2020:688–772. doi:10.1016/B978-0-323-59496-7.00033-5

  3. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: IDEXX quantitative research with dog owners in Europe, December 2024 (n = 1,251). Regions surveyed included the United Kingdom, Germany, France, Spain, and Italy.

  4. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Practice data collected March 2025–January 2026.

  5. Connell D, Nascimento A, Helm Z, Michael H. Early detection of lymphoma by IDEXX Cancer Dx testing in 7 cases. Poster presented at: Veterinary Cancer Society Annual Conference; September 25–27, 2025; Salt Lake City, UT.

  6. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories in North America between 1 November 2024 and 6 December 2024. Analysis Report: IDEXX Cancer Dx Validation, 100282 [008_CancerDx-Validation-Report-2. Rmd].

  7. Nascimento A, Connell D, Lyons H, et al. Analytical validation of a multimodal diagnostic assay for the detection and phenotypic classification of canine lymphoma. Poster presented at: Veterinary Cancer Society Annual Conference; September 25–27, 2025; Salt Lake City, UT.

  8. Nascimento A, Peterson S, Connell D, Helm Z, Venable R. Pilot Evaluation of IDEXX Cancer Dx testing for monitoring CHOP treatment response in canine lymphoma. Poster presented at: Veterinary Cancer Society Annual Conference; September 25 –27, 2025; Salt Lake City, UT.

Media Relations

[email protected]

Investor Relations

[email protected]

KEYWORDS: Maine Europe United States United Kingdom North America

INDUSTRY KEYWORDS: Health Oncology Veterinary

MEDIA:

Photo
Photo
IDEXX Cancer Dx Panel with lymphoma testing
Logo
Logo

Brookfield Wealth Solutions Completes Acquisition of Just Group

Acquisition significantly expands Brookfield Wealth Solutions’ international operations

With the support of Brookfield Wealth Solutions’ permanent capital and strong investment capabilities, Just is now well-positioned to scale its presence in the high growth U.K. pension risk transfer market

BROOKFIELD NEWS, April 01, 2026 (GLOBE NEWSWIRE) — Brookfield Wealth Solutions (“BWS”) today announced the completion of its £2.4 billion ($3.2 billion) acquisition of Just Group Plc. (“Just”).

Just is a leading provider of retirement services in the U.K. pension risk transfer and individual annuity markets. Just has over 700,000 customers and manages £30 billion of pension savings.

Sachin Shah, CEO of Brookfield Wealth Solutions, said: “We’re delighted to welcome Just to Brookfield Wealth Solutions, and we look forward to building on the company’s strong commitment to serving its policyholders. We will draw on our permanent capital and Brookfield’s leading investment capabilities as we support Just’s continued growth as a scaled leader in the U.K. annuity market.”

With BWS’ support, Just is well-positioned to capture growth in the U.K. pension risk transfer market, where projections estimate £40-50 billion of pension liabilities will transfer to insurers annually in the coming years. The acquisition of Just significantly expands BWS’ U.K. presence and international operations and increases its global insurance assets under management to approximately $180 billion.

As part of the transaction, Sir Nigel Wilson has been appointed as Independent Chair of Just. Sir Nigel was CEO of the U.K.’s Legal & General Group Plc from 2012 to 2024.

The transaction was approved by the Prudential Regulation Authority and the Financial Conduct Authority, both of which were constructive throughout the process.

Brookfield is one of the largest private investors in the U.K. with approximately £70 billion (over $90 billion) invested in sectors critical to the economy, including high-quality, long-term infrastructure and real estate.

About Brookfield Wealth Solutions

Brookfield Wealth Solutions Ltd. (NYSE, TSX: BNT) is focused on securing the financial futures of individuals and institutions through a range of retirement services, wealth protection products and tailored capital solutions. Each class A exchangeable limited voting share of Brookfield Wealth Solutions is exchangeable on a one-for-one basis with a class A limited voting share of Brookfield Corporation (NYSE, TSX: BN). 

For more information, please visit our website at bnt.brookfield.com

Brookfield Media: Brookfield Investor Relations:
Marie Fuller Rachel Powell
Email: [email protected] Email: [email protected]
Tel: +44 207 408 8375 Tel: +1 416 956 5141
   


Notice to Readers

This news release and any related oral statements made by our representatives may contain “forward-looking information” within the meaning of Canadian provincial securities laws, “forward-looking statements” within the meaning of Canadian provincial securities laws, “forward-looking statements” within the meaning of the U.S. Securities Act of 1933, the U.S. Securities Exchange Act of 1934, and “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 and in any applicable Canadian securities regulations (collectively, “forward-looking statements”). Forward-looking statements include statements that are predictive in nature, depend upon or refer to future results, events or conditions, and include, but are not limited to, statements which reflect management’s current estimates, assumptions and expectations regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, strategies, capital management and outlook of Brookfield Wealth Solutions and its subsidiaries, as well as the outlook for international economies for the current fiscal year and subsequent periods. In some cases, forward-looking statements can be identified by the use of forward-looking terminology such as “believes,” “thinks,” “expects,” “potential,” “anticipates,” “plans,” “believes,” “estimates,” “seeks,” “intends,” “targets,” “projects,” “foresees,” “forecasts,” or negative versions thereof and other similar expressions, or future or conditional verbs such as “may,” “will,” “should,” “would” and “could.” In particular, the forward-looking statements contained in this news release include statements regarding Just’s future capital strength and its ability to identify future growth opportunities constitute forward-looking statements.

Although we believe that our anticipated future results, performance or achievements expressed or implied by the forward-looking statements and information are based upon reasonable estimates, assumptions and expectations, the reader should not place undue reliance on forward-looking statements and information because they involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, which may cause the actual results, performance or achievements of Brookfield Wealth Solutions or its subsidiaries to differ materially from anticipated future results, performance or achievement expressed or implied by such forward-looking statements and information. 

Factors that could cause actual results to differ materially from those contemplated or implied by forward-looking statements include, but are not limited to: (i) investment returns that are lower than target; (ii) the impact or unanticipated impact of general economic, political and market factors in the countries in which we do business; (iii) the behavior of financial markets, including fluctuations in interest and foreign exchange rates and heightened inflationary pressures; (iv) global equity and capital markets and the availability of equity and debt financing and refinancing within these markets; (v) strategic actions including acquisitions and dispositions; (vi) the ability to complete and effectively integrate acquisitions into existing operations and the ability to attain expected benefits; (vii) changes in accounting policies and methods used to report financial condition (including uncertainties associated with critical accounting assumptions and estimates); (viii) the ability to appropriately manage human capital; (ix) the effect of applying future accounting changes; (x) business competition; (xi) operational and reputational risks; (xii) technological change; (xiii) changes in government regulation and legislation within the countries in which we operate; (xiv) governmental investigations and sanctions; (xv) litigation; (xvi) changes in tax laws; (xvii) ability to collect amounts owed; (xviii) catastrophic events, including but not limited to, earthquakes, hurricanes, epidemics and pandemics; (xix) the possible impact of international conflicts and other developments including terrorist acts and cyberterrorism; (xx) the introduction, withdrawal, success and timing of business initiatives and strategies; (xxi) the failure of effective disclosure controls and procedures and internal controls over financial reporting and other risks; (xxii) health, safety and environmental risks; (xxiii) the maintenance of adequate insurance coverage; (xix) the existence of information barriers between certain businesses within our asset management operations; (xxv) risks specific to our business segments; and (xxvi) factors detailed from time to time in our documents filed with the securities regulators in Canada and the United States.

We caution that the foregoing list of important factors that may affect future results is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the foregoing risks, as well as other uncertainties, factors and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such forward-looking information. Except as required by law, Brookfield Wealth Solutions undertakes no obligation to publicly update or revise any forward-looking statements or information, whether written or oral, whether as a result of new information, future events or otherwise.

Past performance is not indicative nor a guarantee of future results. There can be no assurance that comparable results will be achieved in the future, that future investments will be similar to the historic investments discussed herein, that targeted returns, growth objectives, diversification or asset allocations will be met or that an investment strategy or investment objectives will be achieved (because of economic conditions, the availability of investment opportunities or otherwise).



Versigent Launches as New Publicly Traded Company

Versigent Launches as New Publicly Traded Company

Company Positioned for Success and Value Creation as Leading Global Provider of Signal, Data & Power Distribution Systems

  • Versigent to Begin Trading on the New York Stock Exchange (NYSE) as “VGNT” Effective Today
  • Executive Team to Ring NYSE Opening Bell April 1, 2026

SCHAFFHAUSEN, Switzerland–(BUSINESS WIRE)–Versigent PLC (NYSE: VGNT) today announced the completion of its separation from Aptiv PLC (NYSE: APTV) and its launch as an independent, publicly traded company. Versigent’s shares will begin trading on the New York Stock Exchange (NYSE) under the ticker symbol “VGNT” today where members of the Company’s leadership team are scheduled to ring the Opening Bell.

Versigent is a global leader in the design, manufacturing, and delivery of low- and high-voltage power electrical architectures. With engineering centers on four continents and manufacturing operations in more than 25 countries, Versigent combines global scale with regional responsiveness to serve customers across growing end markets.

“Today marks an important milestone as Versigent begins its next chapter as an independent company built on a century of leadership in advanced power distribution solution systems,” said Joseph Liotine, Chief Executive Officer of Versigent. “As demand grows for greater capability with less complexity, our unmatched combination of engineering expertise, advanced manufacturing excellence, and global scale gives us a distinct advantage. Versigent is purpose-built to amplify our customers’ urgent needs to power smarter, faster, and safer features without compromise.”

Versigent launches with approximately $8.8 billion of revenue, $528 million of net income and $893 million of adjusted EBITDA in 2025, supported by industry‑leading design and engineering capabilities, advanced manufacturing expertise, and a broad global production footprint.

Versigent enters the public markets with a cash generative business model and a strong balance sheet that supports disciplined reinvestment and shareholder returns. As an independent company, Versigent will continue to prioritize operational excellence, distinctive innovation and disciplined capital allocation aligned with long-term value creation.

“Versigent is well positioned to unlock greater value as we enter the public markets,” said Doug Ostermann, Chief Financial Officer of Versigent. “We launch with clear priorities and a strong financial profile, including top-line revenue growth of more than three percent and industry-leading double-digit EBITDA margins that we expect to expand by more than 200 basis points over the next three years. Our business is globally scaled, highly engineered and consistently cash-generative, with a path to $1 billion in free cash flow by 2028. Through a balanced and disciplined capital allocation strategy, we are investing thoughtfully in the business while prioritizing attractive returns for shareholders.”

The separation as an independent, publicly traded company was completed through the distribution, effective April 1, 2026 at 12:01 a.m., Eastern Standard Time, of all the issued and outstanding ordinary shares of Versigent to Aptiv shareholders of record as of the close of business on March 17, 2026, the record date for the distribution. Aptiv shareholders received one ordinary share of Versigent for every three shares of Aptiv common stock held. Aptiv shareholders of record will also receive cash in lieu of any fractional shares to which they would otherwise be entitled. The transaction was completed as a tax-free spin-off for both Swiss and U.S. federal income tax purposes.

Versigent will announce first quarter business results on May 5, 2026 with a conference call occurring at 4:15 p.m. ET., which can be accessed by visiting www.ir.versigent.com.

Versigent operated as part of Aptiv prior to the separation on April 1st 2026. The historical financial measures presented in this release were derived from Aptiv’s accounting records and are presented on a carve-out basis.

About Versigent

Versigent is a global leader in the purposeful design and advanced manufacturing of low and high voltage electrical architectures. Building on a legacy of engineering excellence and trusted partnerships, Versigent delivers versatile, intelligent solutions engineered to unlock greater capabilities for our customers. Powering one in six passenger vehicles in production today, Versigent’s high performance signal, power, and data distribution systems are trusted by industry leaders across automotive, commercial vehicles, agriculture and energy storage. With engineering and manufacturing centers on four continents and operations in more than 25 countries, Versigent’s 138,000 employees match global scale with regional responsiveness to deliver consistent quality and reliable performance connecting the world to faster, smarter and safer experiences. Visit www.versigent.com.

Forward-Looking Statements

This press release contains forward-looking statements that reflect, when made, Versigent’s current views with respect to current events, business plans and financial performance. Such forward-looking statements are subject to many risks, uncertainties and factors relating to Versigent’s operations and business environment, which may cause the actual results of Versigent to be materially different from any future results, express or implied, by such forward-looking statements. All statements that address future operating, financial or business performance or Versigent’s strategies or expectations are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Factors that could cause actual results to differ materially from these forward-looking statements are discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Versigent’s information statement included in its registration statement on Form 10 filed with the Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for Versigent to predict these events or how they may affect Versigent. It should be remembered that the price of the ordinary shares and any income from them can go down as well as up. Versigent disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events and/or otherwise, except as may be required by law.

Use of Non-GAAP Financial Information

This press release contains information about Versigent’s financial results which are not presented in accordance with GAAP. Specifically, Adjusted EBITDA is a non-GAAP financial measure.

Management believes the non-GAAP financial measure used in this press release is useful to both management and investors in their analysis of the Company’s financial position, results of operations and liquidity. In particular, management believes Adjusted EBITDA is a useful measure in assessing the Company’s ongoing financial performance that, when reconciled to the corresponding GAAP measure, provides improved comparability between periods through the exclusion of certain items that management believes are not indicative of the Company’s core operating performance and that may obscure underlying business results and trends. Management also uses the non-GAAP financial measure for internal planning and forecasting purposes.

The non-GAAP financial measure included in this press release is reconciled to the most directly comparable GAAP financial measure in the attached supplemental schedule at the end of this press release. Non-GAAP measures should not be considered in isolation or as a substitute for our reported results prepared in accordance with GAAP and, as calculated, may not be comparable to other similarly titled measures of other companies.

Adjusted EBITDA: Adjusted EBITDA is presented as a supplemental measure of the Company’s financial performance which management believes is useful to investors in assessing the Company’s ongoing financial performance that, when reconciled to the corresponding U.S. GAAP measure, provides improved comparability between periods through the exclusion of certain items that management believes are not indicative of the Company’s core operating performance and which may obscure underlying business results and trends. Our management utilizes Adjusted EBITDA in its financial decision-making process to evaluate performance of the Company and for internal reporting, planning and forecasting purposes. Adjusted EBITDA is defined as net income before depreciation and amortization (including asset impairments), interest expense, income tax (expense) benefit, other income (expense), net, equity income (loss), net of tax, restructuring, other acquisition and portfolio project costs (which includes costs incurred to integrate acquired businesses and to plan and execute product portfolio transformation actions, including business and product acquisitions and divestitures), and other special items. Not all companies use identical calculations of Adjusted EBITDA, therefore this presentation may not be comparable to other similarly titled measures of other companies.

Consolidated Adjusted EBITDA (Unaudited)

 

 

Year Ended December 31,

 

2025

 

(in millions)

Net income attributable to Versigent

$

528

 

Interest income

 

(3

)

Income tax benefit

 

(6

)

Net income attributable to noncontrolling interest

 

18

 

Depreciation and amortization

 

227

 

EBITDA

$

764

 

Other expense, net

 

10

 

Equity income, net of tax

 

(13

)

Restructuring

 

86

 

Separation costs

 

42

 

Other acquisition and portfolio project costs

 

4

 

Adjusted EBITDA

$

893

 

 

Press contact:

Annalisa Esposito Bluhm, Vice President Corporate Communications and Marketing, Phone: +1.248.817.7990, email: [email protected]

Investor Relations:

email: [email protected]

KEYWORDS: Europe Switzerland United States North America

INDUSTRY KEYWORDS: Data Management Automotive Manufacturing Automotive Technology Manufacturing General Automotive Autonomous Driving/Vehicles Vehicle Technology Software Engineering Hardware

MEDIA:

Logo
Logo

WeRide and Grab Officially Launch Singapore’s First Autonomous Public Ride Service in Punggol

  • The Ai.R (Autonomously Intelligent Ride) service is operated by Grab and features WeRide’s GXR and Robobus autonomous vehicle (AV) models. 
  • The Ai.R fleet has successfully served more than 1,000 early riders and clocked over 30,000km of autonomous mileage.
  • The development of the Ai.R service has unlocked new career paths for Grab’s driver-partners, including roles such as Safety Operator and Remote Operator.
  • Interested members of the public can now register to experience the AV service (visit


    rideair.ai


    to reserve your ride).

SINGAPORE, March 31, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, and Grab (NASDAQ: GRAB), Southeast Asia’s leading superapp, today officially commenced public operations for the Ai.R (Autonomously Intelligent Ride) service in Punggol. Starting today, the public can experience Singapore’sfirst autonomous passenger service ever deployed within a residential estate.


WeRide and Grab’s GXR in Punggol

The transition to public service follows a rigorous community engagement phase. Since January 2026, more than 1,000 passengers — including Punggol residents and community leaders — trialled the service and provided feedback that has improved the ride experience. To date, the Ai.R fleet has safely clocked 30,000km of autonomous mileage.

“WeRide is proud to deliver Singapore’s first autonomous public ride service in the Punggol district. This achievement reflects our technological readiness and shared commitment with Grab to advance the future of urban mobility. Our GXR vehicles already operate as taxis in China, the UAE, and Saudi Arabia, providing safe and reliable point-to-point on-demand transport to our riders. We look forward to bringing the same proven performance to Singapore, in close coordination with local authorities, as operations scale and mature,” said Dr. Kerry Xu, General Manager of Singapore at WeRide.

“Grab is delighted to be bringing the first autonomous vehicle service in a residential area to the public. This service is about more than just deploying state-of-the-art AVs, it is about building a future where technology and the community move forward together. By integrating autonomous rides into the daily lives of Punggol residents and upskilling Grab’s driver-partners into new roles, we are ensuring that the benefits of innovation are shared by all. We are excited to take this significant step toward a more seamless and sustainable transport ecosystem for Singapore,” said Alejandro Osorio, Managing Director of Grab Singapore.

Empowering driver-partners for new AV roles

As WeRide and Grab embark on the integration of AV technologies, their key focus has also been preparing the workforce for an autonomous future.

During the initial phase of public rides, Safety Operators will be onboard the AVs to help ensure a seamless journey. To date, 14 Grab driver-partners have successfully completed specialised training with WeRide and GrabAcademy to become certified Safety Operators and another batch of Grab driver-partners are currently undergoing training and assessments.

WeRide and GrabAcademy have also commenced Remote Operator training, where participants learn how to monitor the fleet remotely from the Ai.R Operations Command Centre.

Vincent Teo, a long-time Grab driver-partner who recently transitioned to the role of a Safety Operator, is now among the first to undergo the Remote Operator programme. He shared “I am incredibly excited to progress towards Remote Operator training. When I first started this journey, I never imagined I’d have the opportunity to be at the absolute forefront of such advanced technology. This is a huge milestone for me personally — and I’m proud to be part of the team bringing this future to fellow Singaporeans.”

Ridhwan Wajib, a Grab driver-partner who recently took on the role of Safety Operator, said “It’s a privilege to be one of the first in this field. This role has been such an interesting journey that I’m constantly telling my loved ones all about it. More than anything, I’m looking forward to the moment my parents and my family step on board to experience this technology with me.”

Inviting the public to ride with Ai.R today

The public can register for rides on the Ai.R fleet via a dedicated reservation link on the Ai.R website (visit rideair.ai to reserve your ride). Designed in consultation with the community, the routes connect residents to key amenities and transport nodes.

During the public ride phase, passengers can select their preferred routes and timings:

  • Operating hours: The Ai.R fleet operates on weekdays (Monday–Friday) from 9:30 AM to 5:30 PM.
  • Routes: Riders can choose between two full AV shuttle routes. A 20-minute “Mini Route” will also be offered for those looking for a shorter AV experience.
  • Fares: Rides will be free till commercial service begins in mid-2026, allowing more passengers to share their feedback, as well as gathering insights into usage patterns, to help to fine-tune service and pricing standards for the introductory discounted fare.

Driving the future of mobility


The launch of Ai.R service underscores WeRide and Grab’s commitment to deploy robotaxis and autonomous shuttles in Southeast Asia.
Moving from the first Milestone 1 (M1) assessment to full public operations in about seven months, the project’s momentum highlights the maturity of WeRide’s technology, Grab’s operational and technical capabilities, as well as the close collaboration with the government. As active members of Singapore’s Steering Committee on Autonomous Vehicles, WeRide and Grab continue to work alongside the government to ensure AVs are safely integrated into the national transport system.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 12 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune’s 2025 Change the World and 2025 Future 50 lists.

About Grab

Grab is a leading superapp in Southeast Asia, operating across the deliveries, mobility and digital financial services sectors. Serving over 900 cities in eight Southeast Asian countries — Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam — Grab enables millions of people everyday to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending and insurance, all through a single app. We operate supermarkets in Malaysia under Jaya Grocer and Everrise, which enables us to bring the convenience of on-demand grocery delivery to more consumers in the country. As part of our financial services offerings, we also provide digital banking services through GXS Bank in Singapore and GXBank in Malaysia. Grab was founded in 2012 with the mission to drive Southeast Asia forward by creating economic empowerment for everyone. Grab strives to serve a triple bottom line — we aim to simultaneously deliver financial performance for our shareholders and have a positive social impact, which includes economic empowerment for millions of people in the region, while mitigating our environmental footprint.

Media Contacts


[email protected]


[email protected]

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c439a69c-a941-415c-8700-4948107580b7



uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline – Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

  • Who is Involved: uniQure N.V. (NasdaqGS: QURE) investors that purchased between September 24, 2025 and October 31, 2025
  • When to Act: Deadline to file Lead Plaintiff applications is April 13, 2026
  • Basis: uniQure shares fell on disclosure of FDA approval delay for AMT-130 Application

NEW YORK and NEW ORLEANS, March 31, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until April 13, 2026 to file lead plaintiff applications in a securities class action lawsuit against uniQure N.V. (NasdaqGS: QURE) (“uniQure” or the “Company”), if they purchased or otherwise acquired the Company’s shares between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

What You May Do

If you purchased shares of uniQure and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-qure/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by April 13, 2026.

About the Lawsuit

uniQure and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

During the Class Period, the Company represented to investors that there was a high likelihood that its leading drug candidate, AMT-130, would receive accelerated approval from the U.S. Food and Drug Administration (“FDA”) after the Company’s planned Biologics License Application (“BLA”) submission in the first quarter of 2026. However, on November 3, 2025, the Company disclosed that “the FDA currently no longer agrees that the data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission” and as a result, “the timing of the BLA submission for AMT-130 is now unclear.”

On this news, the price of uniQure’s shares plummeted $33.40 per share, or more than 49%, from a close of $67.69 per share on October 31, 2025, to close at $34.29 per share on November 3, 2025.

The case is Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn



Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc – CNTA

Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc – CNTA

NEW YORK CITY & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Kahn Swick & Foti, LLC
Lewis S. Kahn
KSF Managing
[email protected]
855-768-1857

KEYWORDS: Louisiana New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit – Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, March 31, 2026 (GLOBE NEWSWIRE) — Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://www.ksfcounsel.com/cases/nasdaqgs-rare/

Ultragenyx investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-rare/ to learn more.

CASE DETAILS:   On December 26, 2025, the Company announced the “results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta” disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company “is evaluating its planned operations and will promptly define and implement significant expense reductions.”   On this news, the price of Ultragenyx’s shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.

The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.

WHAT TO DO? If you invested in Ultragenyx and suffered a loss during the relevant time frame, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms – According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn